Target intelligence / Profile preview

Ras-related GTP-binding protein C (RagC) (RagC)

Target
RagC
Molecular classification
GTPase, Small GTPase, mTORC1 regulator, Ras-related protein
01

Overview

Ras-related GTP-binding protein C (RagC) is a small GTPase that plays a pivotal role in the nutrient-sensing pathway that activates the mechanistic target of rapamycin complex 1 (mTORC1). It functions as part of a heterodimer with RagA or RagB to recruit mTORC1 to the lysosomal surface, where it can be activated by Rheb. Recent research has identified that specific lysine residues on RagC (K15, K23, and K211) undergo β-hydroxybutyrylation (Kbhb), a post-translational modification induced by elevated levels of the ketone body β-hydroxybutyrate (BHB) during fasting or ketogenic states (He et al., 2024, Molecular Cell). This modification is catalyzed by the acetyltransferase p300 and serves to enhance the interaction between RagC and the mTORC1 component Raptor, thereby driving mTORC1 signaling independently of amino acid levels. In pathological contexts, such as hepatocellular carcinoma, this mechanism allows tumor cells to maintain growth signals even in nutrient-poor environments, identifying RagC β-hydroxybutyrylation as a potential therapeutic target. While direct inhibitors of RagC Kbhb are not yet clinically available, the pathway can be modulated via p300 inhibitors or HDAC inhibitors, which act as the "writer" and "eraser" of this modification, respectively. Targeting this specific metabolic-epigenetic axis offers a novel approach to treating cancers and metabolic diseases characterized by dysregulated mTORC1 activity.

Other names
RRAGCGTPase RagCTIBESRas-related GTP-binding protein Cβ-hydroxybutyrylated RagC
02

Mechanism of action

Inhibition of p300-mediated β-hydroxybutyrylation of RagC to prevent mTORC1 lysosomal recruitment and subsequent activation.

03

Biological functions

mTORC1 signalingNutrient sensingLysosomal recruitmentCell growthMetabolic regulation
04

Disease associations

CancerHepatocellular carcinomaFollicular lymphomaMetabolic disorders
05

Safety considerations

Off-target effects of p300/HDAC inhibitionImpairment of normal metabolic adaptation to fastingSystemic mTORC1 inhibition side effects
06

Interacting drugs

A-485

3 more in the full profile.

07

Biomarkers

RagC K15/K23/K211 β-hydroxybutyrylationSerum β-hydroxybutyrate (BHB)Phospho-S6K1

Beyond the preview

Go deeper on Ras-related GTP-binding protein C (RagC) (RagC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras-related GTP-binding protein C (RagC) (RagC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call